These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33619887)

  • 41. Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
    Yang X; Dai H; Kang L; Qu C; Li Z; Yin J; Qiu H; Fu C; Han Y; Jin Z; Ma X; Zhu X; Yu L; Wu D; Tang X
    Hematol Oncol; 2019 Dec; 37(5):655-658. PubMed ID: 31656047
    [No Abstract]   [Full Text] [Related]  

  • 42. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
    Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
    Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation.
    Zhao XY; Xu ZL; Mo XD; Chen YH; Lv M; Cheng YF; Chen H; Chang YJ; Xu LP; Wang Y; Zhang XH; Liu KY; Huang XJ
    Leukemia; 2022 Jan; 36(1):267-270. PubMed ID: 34285344
    [No Abstract]   [Full Text] [Related]  

  • 44. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.
    Fujishima N; Uchida T; Onishi Y; Jung CW; Goh YT; Ando K; Wang MC; Ono C; Matsumizu M; Paccagnella ML; Sleight B; Vandendries E; Fujii Y; Hino M
    Int J Hematol; 2019 Dec; 110(6):709-722. PubMed ID: 31655984
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.
    Short NJ; Kantarjian H; Jabbour E
    Leukemia; 2021 Nov; 35(11):3044-3058. PubMed ID: 34172894
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report.
    Wen S; Niu Z; Xing L; Wang Y; Li H; Kuang N; Luo J; Zhang X; Wang F
    BMC Cancer; 2018 Nov; 18(1):1143. PubMed ID: 30458755
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead.
    Pasvolsky O; Kebriaei P; Shah BD; Jabbour E; Jain N
    Blood Adv; 2023 Jul; 7(14):3350-3360. PubMed ID: 36912764
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease.
    Curran E; O'Brien M
    Semin Hematol; 2020 Jul; 57(3):157-163. PubMed ID: 33256906
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
    Bhojwani D; Sposto R; Shah NN; Rodriguez V; Yuan C; Stetler-Stevenson M; O'Brien MM; McNeer JL; Quereshi A; Cabannes A; Schlegel P; Rossig C; Dalla-Pozza L; August K; Alexander S; Bourquin JP; Zwaan M; Raetz EA; Loh ML; Rheingold SR
    Leukemia; 2019 Apr; 33(4):884-892. PubMed ID: 30267011
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Allogeneic Stem Cell Transplantation after Salvage Inotuzumab Ozogamicin: A Happy Ending?
    Ai J
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):e273-e274. PubMed ID: 31260801
    [No Abstract]   [Full Text] [Related]  

  • 52. [Sequential therapy with inotuzumab ozogamicin followed by CAR T-cell therapy for Philadelphia chromosome-negative acute lymphoblastic leukemia].
    Mizutani Y; Kusakabe S; Fukushima K; Murakami H; Hamada M; Hasegawa C; Mizuta E; Yamaguchi Y; Nakai R; Kurashige R; Hino A; Ueda T; Fujita J; Miyamura T; Hosen N
    Rinsho Ketsueki; 2024; 65(2):78-83. PubMed ID: 38448002
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.
    DeAngelo DJ; Advani AS; Marks DI; Stelljes M; Liedtke M; Stock W; Gökbuget N; Jabbour E; Merchant A; Wang T; Vandendries E; Neuhof A; Kantarjian H; O'Brien S
    Blood Cancer J; 2020 Aug; 10(8):81. PubMed ID: 32769965
    [TBL] [Abstract][Full Text] [Related]  

  • 54. What is the Role of Hematopoietic Cell Transplantation (HCT) for Pediatric Acute Lymphoblastic Leukemia (ALL) in the Age of Chimeric Antigen Receptor T-Cell (CART) Therapy?
    Taraseviciute A; Broglie L; Phelan R; Bhatt NS; Becktell K; Burke MJ
    J Pediatr Hematol Oncol; 2019 Jul; 41(5):337-344. PubMed ID: 30973486
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful treatment of the first adult case of ZMIZ1::ABL1-positive B cell lymphoblastic leukemia with dasatinib, chimeric antigen receptor T-cell therapy, and allogeneic hematopoietic stem cell transplantation.
    Chen X; Yuan L; Ma X; Cao P; Wang F; Zhang Y; Chen J; Zhang X; Zhao Y; Liu H
    Cancer Genet; 2024 Jun; 284-285():16-19. PubMed ID: 38503133
    [No Abstract]   [Full Text] [Related]  

  • 56. New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia.
    Lanza F; Maffini E; Saraceni F; Massari E; Rondoni M; Daghia G; Olivieri A; Cerchione C; Martinelli G
    Minerva Med; 2020 Oct; 111(5):478-490. PubMed ID: 32955830
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome.
    Chen L; Xu B; Long X; Gu J; Lou Y; Wang D; Cao Y; Wang N; Li C; Wang G; Wang Y; Zhu L; Wang J; An H; Xiao M; Xiao Y; Zhou J
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345625
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful Salvage of Very Early Relapse in Pediatric Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin and HLA-haploidentical Peripheral Blood Stem Cell Transplantation With Posttransplant Cyclophosphamide.
    Abematsu T; Nishikawa T; Nakagawa S; Kodama Y; Okamoto Y; Kawano Y
    J Pediatr Hematol Oncol; 2022 Mar; 44(2):62-64. PubMed ID: 33512872
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune therapies of B-cell acute lymphoblastic leukaemia in children and adults.
    Kegyes D; Ghiaur G; Bancos A; Tomuleasa C; Gale RP
    Crit Rev Oncol Hematol; 2024 Apr; 196():104317. PubMed ID: 38437908
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy.
    Yurkiewicz I; Craig J; Muffly L
    Curr Hematol Malig Rep; 2020 Jun; 15(3):187-193. PubMed ID: 32358681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.